Idarubicin, ara-c, and topotecan in patients with refractory or relapased acute myelogenous leukemia and high-risk myelodysplastic syndrome.

被引：0
|
作者：
Min, YH [1 ]
Jang, JH [1 ]
Lee, ST [1 ]
Hahn, JS [1 ]
Ko, YW [1 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4251
引用
收藏
页码：234B / 234B
页数：1
相关论文
共 50 条
  • [21] High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study
    Alessandra Tedeschi
    Marco Montillo
    Elena Strocchi
    Anna Maria Cafro
    Elisabetta Tresoldi
    Liliana Intropido
    Michele Nichelatti
    Laura Marbello
    Claudia Baratè
    Carlo Maurizio Camaggi
    Enrica Morra
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 771 - 779
  • [22] Modified topotecan combination with cyclophosphamide and ara-c (CAT) for patients with Refractory/Relapsed leukemia
    Wu, Sui-jing
    Du, Xin
    Lin, Wei
    Huang, Zi-lun
    Zhou, Xiao-li
    Weng, Jian-yu
    Zhong, Li-ye
    Lu, Ze-sheng
    BLOOD, 2007, 110 (11) : 157B - 157B
  • [23] CMA 676 in combination with ARA-C and liposomal daunorubicin high risk acute myelogenous leukemia patients.
    Günzelmann, S
    Fauser, AA
    Koldehoff, M
    Basara, N
    Kiehl, MG
    BLOOD, 2001, 98 (11) : 257B - 257B
  • [24] CHILDHOOD ACUTE MYELOGENOUS LEUKEMIA (AML) REFRACTORY TO ANTHRACYCLINE CYTARABINE (ARA-C) THERAPIES
    KALWINSKY, D
    LOOK, AT
    MIRRO, J
    DAHL, GV
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 193 - 193
  • [25] Predictors and Outcome of Acute Kidney Injury in Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome
    Lahoti, Amit
    Kantarjian, Hagop
    Salahudeen, Abdulla K.
    Ravandi, Farhad
    Cortes, Jorge E.
    Faderl, Stefan
    O'Brien, Susan
    Wierda, William
    Mattiuzzi, Gloria N.
    CANCER, 2010, 116 (17) : 4063 - 4068
  • [26] Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
    Borthakur, Gautam
    Estrov, Zeev
    Garcia-Manero, Guillermo
    Williams, Betsy
    Wathen, Jay K.
    Konopleva, Marina
    Burger, Jan
    Ferrajoli, Alessandra
    George, Solly
    Kantarjian, Hagop
    BLOOD, 2008, 112 (11) : 1026 - 1026
  • [27] Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Konopleva, Marina
    Burger, Jan A.
    O'Brien, Susan
    Ferrajoli, Alessandra
    Verstovsek, Srdan
    Kadia, Tapan M.
    Jabbour, Elias J.
    Faderl, Stefan
    Diaz-Pines-Mateo, Maria
    Pemmaraju, Naveen
    Pierce, Sherry A.
    Cortes, Jorge E.
    Borthakur, Gautam
    BLOOD, 2012, 120 (21)
  • [28] Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)
    A. Ganser
    G. Heil
    G. Seipelt
    W. Hofmann
    J. T. Fischer
    W. Langer
    W. Brockhaus
    K. Kolbe
    T. H. Ittel
    N. Brack
    H. G. Fuhr
    P. Knuth
    K. Höffken
    L. Bergmann
    D. Hoelzer
    Annals of Hematology, 2000, 79 : 30 - 35
  • [29] A single high dose of idarubicin combined with high dose ARA-C for the treatment of first recurrent childhood "high-risk" acute lymphoblastic leukemia (ALL).
    Testi, AM
    Del Giudice, I
    Arcese, W
    Moleti, ML
    Giona, F
    Arico, M
    Basso, G
    Conter, V
    Messina, C
    Rondelli, R
    Uderzo, C
    Micalizzi, MC
    Barisone, E
    Locatelli, F
    Dini, G
    Casale, F
    Valsecchi, MG
    Masera, G
    Mandelli, F
    BLOOD, 2000, 96 (11) : 719A - 719A
  • [30] Cladribine, Idarubicin, Cytarabine (araC), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Reville, Patrick K.
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    DiNardo, Courtney D.
    Andreeff, Michael
    Daver, Naval
    Jain, Nitin
    Kornblau, Steven M.
    Jabbour, Elias
    Short, Nicholas J.
    Alvarado, Yesid
    Ohanian, Maro
    Bose, Prithviraj
    Masarova, Lucia
    Wang, Sa A.
    Tidwell, Rebecca S. S.
    Estrov, Zeev E.
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2020, 136
12345